Harvoni (Gilead Sciences, Inc)
Welcome to the PulseAid listing for the Harvoni drug offered from Gilead Sciences, Inc. This Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Gilead Sciences, Inc |
| NON-PROPRIETARY NAME: | LEDIPASVIR and SOFOSBUVIR |
| SUBSTANCE NAME: | LEDIPASVIR; SOFOSBUVIR |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2014-10-10 |
| END MARKETING DATE: | 0000-00-00 |
Harvoni HUMAN PRESCRIPTION DRUG Details:
| Item Description | Harvoni from Gilead Sciences, Inc |
| LABELER NAME: | Gilead Sciences, Inc |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 90; 400(mg/1; mg/1) |
| START MARKETING DATE: | 2014-10-10 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 61958-1801_003a653b-d337-4997-aa04-1e78a9c313d4 |
| PRODUCT NDC: | 61958-1801 |
| APPLICATION NUMBER: | NDA205834 |
Other LEDIPASVIR; SOFOSBUVIR Pharmaceutical Manufacturers / Labelers:
